AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24080704 — intervention group
Group type: COMPARATOR
Intervention: No subclinical diabetic macular edema (DME)
Number of subjects: 348
Study 24081577 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine (20 mg/m² × 5 days) plus low-dose cytarabine (20 mg/m² × 14 days)
Number of subjects: 11
Study 24081739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-induced BAT activity (CIBA) after exposure to 16°C
Number of subjects: 16
Study 24081739 — intervention group
Group type: EXPERIMENTAL
Intervention: CIBA after fasting (n = 6)
Number of subjects: 16
Study 24081739 — intervention group
Group type: EXPERIMENTAL
Intervention: CIBA after 24 hours of overfeeding (n = 8)
Number of subjects: 16
Study 24081739 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CIBA
Number of subjects: 16
Study 24081970 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricuspid-valve regurgitant jet velocity ≥3.2 m/s
Number of subjects: 1309
Study 24081970 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed PAH
Number of subjects: 1309
Study 24081970 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1309
Study 24081970 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 1309
Study 24081973 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation in patients with IPAH
Number of subjects: 1283
Study 24081973 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation in patients with other forms of PAH
Number of subjects: 1283
Study 24082310 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA)
Number of subjects: 833
Study 24082310 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen desaturation index (ODI)
Number of subjects: 833
Study 24082310 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily energy expenditure
Number of subjects: 833
Study 24082310 — intervention group
Group type: EXPERIMENTAL
Intervention: AHI
Number of subjects: 833
Study 24082655 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolomics + morphology group (ViaMetrics-E)
Number of subjects: 125
Study 24082655 — intervention group
Group type: COMPARATOR
Intervention: Morphology group
Number of subjects: 125
Study 24086319 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cotrimoxazole from 1 to 6 months
Number of subjects: 1705
Study 24086319 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic cotrimoxazole exposure
Number of subjects: 1705
Study 24088092 — intervention group
Group type: EXPERIMENTAL
Intervention: Global cognition assessment at 3 months
Number of subjects: 821
Study 24088092 — intervention group
Group type: EXPERIMENTAL
Intervention: Global cognition assessment at 12 months
Number of subjects: 821
Study 24088092 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive function assessment at 3 months
Number of subjects: 821
Study 24088092 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive function assessment at 12 months
Number of subjects: 821
Study 24088306 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk group (SBP >115 mmHg and HR <70 beats/min)
Number of subjects: 3029
Study 24088306 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-risk group (SBP 89-115 mmHg and HR >76 beats/min)
Number of subjects: 3029
Study 24088306 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group (SBP <89 mmHg regardless of HR values)
Number of subjects: 3029
Study 24088548 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 5805
Study 24088719 — intervention group
Group type: EXPERIMENTAL
Intervention: a priori diet-quality score
Number of subjects: 2632
Study 24088719 — intervention group
Group type: EXPERIMENTAL
Intervention: meat dietary pattern
Number of subjects: 2632
Study 24088719 — intervention group
Group type: EXPERIMENTAL
Intervention: fruit-vegetable dietary pattern
Number of subjects: 2632
Study 24088719 — intervention group
Group type: EXPERIMENTAL
Intervention: grains (whole and refined), processed meats, beverages (coffee, meal-replacement drinks, beer, and wine)
Number of subjects: 2632
Study 24088719 — intervention group
Group type: EXPERIMENTAL
Intervention: whole fruit (not juices), organ meats, fried meats and fish, soy and nondairy products
Number of subjects: 2632
Study 24089587 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) 5 mg/kg every 6 weeks for 56 weeks, then reduced to 3 mg/kg every 8 weeks during the second year, with concomitant MTX at median dose 7.5 mg/week.
Number of subjects: 19
Study 24089587 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) treatment
Number of subjects: 19
Study 24089677 — intervention group
Group type: EXPERIMENTAL
Intervention: Endostatin/collagen XVIII
Number of subjects: 30
Study 24090033 — intervention group
Group type: EXPERIMENTAL
Intervention: Home administration of pemetrexed maintenance therapy (500 mg/m² every 3 weeks until progressive disease or unacceptable toxicity)
Number of subjects: 50
Study 24090077 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg oral dose of DMAA
Number of subjects: 7
Study 24090083 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention program (ILI)
Number of subjects: 199
Study 24091564 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical pudendal nerve stimulation (EPNS)
Number of subjects: 106
Study 24091623 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 4541
Study 24091623 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 4541
Study 24091623 — intervention group
Group type: EXPERIMENTAL
Intervention: AI/tamoxifen treatment
Number of subjects: 4541
Study 24091982 — intervention group
Group type: EXPERIMENTAL
Intervention: sunitinib/XP
Number of subjects: 76
Study 24091982 — intervention group
Group type: EXPERIMENTAL
Intervention: sunitinib/XELOX
Number of subjects: 76
Study 24092248 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine use of fractional flow reserve (FFR) during PCI
Number of subjects: 5097
Study 24092248 — intervention group
Group type: COMPARATOR
Intervention: Before routine use of FFR
Number of subjects: 5097
Study 24092248 — intervention group
Group type: EXPERIMENTAL
Intervention: After routine use of FFR
Number of subjects: 5097
Study 24092875 — intervention group
Group type: COMPARATOR
Intervention: SCORE algorithm
Number of subjects: 2321
Study 24092875 — intervention group
Group type: EXPERIMENTAL
Intervention: SCORE-HDL algorithm
Number of subjects: 2321
Study 24092908 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 16/18 vaccination (Cervarix)
Number of subjects: 1000
Study 24092908 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-vaccinated or older women)
Number of subjects: 1000
Study 24092907 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 0
Study 24092933 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (75 mg/m² for 7 days) and Gemtuzumab ozogamicin (3 mg/m² on day 8)
Number of subjects: 142
Study 24093428 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening-like option (unlabelled preference)
Number of subjects: 911
Study 24093428 — intervention group
Group type: EXPERIMENTAL
Intervention: Labelled intent for screening
Number of subjects: 911
Study 24093426 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg CHP-NY-ESO-1 vaccine
Number of subjects: 25
Study 24093426 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg CHP-NY-ESO-1 vaccine
Number of subjects: 25
Study 24093426 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 25
Study 24093540 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) cytokine levels prior to surgery
Number of subjects: 61
Study 24093770 — intervention group
Group type: EXPERIMENTAL
Intervention: Nailfold capillaroscopy
Number of subjects: 26
Study 24093770 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Doppler flowmetry
Number of subjects: 26
Study 24093770 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 26
Study 24093936 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape Up Somerville (SUS) intervention
Number of subjects: 0
Study 24094497 — intervention group
Group type: EXPERIMENTAL
Intervention: Fucosyltransferase VI (FTVI)
Number of subjects: 0
Study 24094497 — intervention group
Group type: EXPERIMENTAL
Intervention: Fucosyltransferase VII (FTVII)
Number of subjects: 0
Study 24094497 — intervention group
Group type: COMPARATOR
Intervention: Mock control
Number of subjects: 0
Study 24094947 — intervention group
Group type: EXPERIMENTAL
Intervention: BSID-III
Number of subjects: 49
Study 24094947 — intervention group
Group type: EXPERIMENTAL
Intervention: VABS-II
Number of subjects: 49
Study 24095149 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic subjects with complications
Number of subjects: 400
Study 24095149 — intervention group
Group type: COMPARATOR
Intervention: Diabetic subjects without complications
Number of subjects: 400
Study 24095149 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper and lower body strength
Number of subjects: 400
Study 24095247 — intervention group
Group type: EXPERIMENTAL
Intervention: Setipiprant capsule (2 250-mg capsules)
Number of subjects: 20
Study 24095247 — intervention group
Group type: EXPERIMENTAL
Intervention: Setipiprant tablet (500-mg tablet)
Number of subjects: 20
Study 24095247 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 20
Study 24097022 — intervention group
Group type: EXPERIMENTAL
Intervention: Step 1 analgesic (mainly paracetamol)
Number of subjects: 1379
Study 24097022 — intervention group
Group type: EXPERIMENTAL
Intervention: Step 2 analgesic (23% dextropropoxyphene and 40.3% tramadol/paracetamol combination)
Number of subjects: 1379
Study 24097022 — intervention group
Group type: EXPERIMENTAL
Intervention: Step 3 analgesics
Number of subjects: 1379
Study 24097022 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic medication
Number of subjects: 1379
Study 24097022 — intervention group
Group type: EXPERIMENTAL
Intervention: No analgesic medication
Number of subjects: 1379
Study 24097372 — intervention group
Group type: EXPERIMENTAL
Intervention: Pace-capture group
Number of subjects: 40
Study 24097372 — intervention group
Group type: COMPARATOR
Intervention: Adenosine group
Number of subjects: 40
Study 24097372 — intervention group
Group type: EXPERIMENTAL
Intervention: Pace-capture group (subset)
Number of subjects: 40
Study 24097843 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (400 mg twice daily)
Number of subjects: 10
Study 24098507 — intervention group
Group type: EXPERIMENTAL
Intervention: Netazepide (YF476) administered orally for 12 weeks
Number of subjects: 8
Study 24099345 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-weekly rifampicin-based therapy
Number of subjects: 305
Study 24099345 — intervention group
Group type: EXPERIMENTAL
Intervention: Low baseline CD4 cell count (<100 cells/mm3)
Number of subjects: 305
Study 24099518 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 immunotherapy (T4(+) T-cells) administered intratumorally at doses starting from 10^7 cells to 10^9 cells.
Number of subjects: 0
Study 24099518 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 immunotherapy (T4(+) T-cells) administered intratumorally with low- or high-dose cyclophosphamide before 10^9 T4(+) T-cells.
Number of subjects: 0
Study 24099518 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine/in-house assays and imaging techniques used to monitor safety, efficacy, perturbation of endogenous antitumor immunity, immunogenicity, and T-cell trafficking.
Number of subjects: 0
Study 24099585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (12 mg/m²)
Number of subjects: 31
Study 24099585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (10 mg/m²)
Number of subjects: 31
Study 24099585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (weekly administration)
Number of subjects: 31
Study 24099585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (6-12 mg/m² doses)
Number of subjects: 31
Study 24099865 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 120 mg/m² and pemetrexed 500 mg/m² intravenously every 21 days
Number of subjects: 47
Study 24100924 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (dose-intense)
Number of subjects: 45
Study 24101038 — intervention group
Group type: EXPERIMENTAL
Intervention: R-MPV followed by rdWBRT (23.4 Gy) and consolidation cytarabine
Number of subjects: 52
Study 24101038 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (N = 52)
Number of subjects: 52
Study 24101373 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis 20 mg QD for 12 months
Number of subjects: 21
Study 24101663 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary patterns including lesser intake of vegetables, fruits, grains, vegetable protein, glutamic acid, starch, fiber, minerals, and potassium; higher intake of processed meats, pork, eggs, and sugar-sweetened beverages; higher cholesterol and higher Na/K ratio.
Number of subjects: 1559
Study 24101663 — intervention group
Group type: COMPARATOR
Intervention: Control for higher body mass index of black women
Number of subjects: 1559
Study 24101663 — intervention group
Group type: COMPARATOR
Intervention: Control for 11 nutrient and 10 non-nutrient correlates
Number of subjects: 1559
Study 24101663 — intervention group
Group type: COMPARATOR
Intervention: Control for foods/urinary metabolites
Number of subjects: 1559
Study 24102029 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (treated with statins)
Number of subjects: 29
Study 24102029 — intervention group
Group type: COMPARATOR
Intervention: Untreated PAD group
Number of subjects: 29
Study 24102029 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 24102758 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 47
Study 24102758 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam
Number of subjects: 47
Study 24103115 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of intussusception (IS) in children < 1 year
Number of subjects: 167
Study 24103115 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of intussusception (IS) in children < 2 years
Number of subjects: 167
Study 24103115 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery outcomes
Number of subjects: 167
Study 24103704 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid revascularisation combining off-pump left internal mammary artery grafting to the LAD through J-hemisternotomy (JOPCAB)
Number of subjects: 100
Study 24103704 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid revascularisation combining JOPCAB with PCI
Number of subjects: 100
Study 24105751 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) 1,000 mg every 3 days
Number of subjects: 150
Study 24105751 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 150
Study 24105925 — intervention group
Group type: EXPERIMENTAL
Intervention: PHD2 silencing in hBM-MSC
Number of subjects: 0
Study 24105925 — intervention group
Group type: EXPERIMENTAL
Intervention: PHD2 inhibition with shRNAs
Number of subjects: 0
Study 24105925 — intervention group
Group type: COMPARATOR
Intervention: Cotransfection with HIF-1α or VEGF-A siRNAs
Number of subjects: 0
Study 24106115 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of the photoreceptor cone outer segment tips (COST) line defect
Number of subjects: 46
Study 24106115 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of the preoperative COST line defect
Number of subjects: 46
Study 24106115 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative BCVA
Number of subjects: 46
Study 24106115 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of IS/OS line defect and ELM line defect
Number of subjects: 46
Study 24106815 — intervention group
Group type: EXPERIMENTAL
Intervention: Active infusion of ropivacaine 0.2% at 5 mL/hr via TAP catheter
Number of subjects: 8
Study 24106815 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion via TAP catheter
Number of subjects: 8
Study 24106841 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with Hope Program (self-administered intervention including a film and a hope activity)
Number of subjects: 36
Study 24106841 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with Hope Program
Number of subjects: 36
Study 24106922 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with 1.8-2.0 ml of 0.75% ropivacaine plus 10 μg of fentanyl
Number of subjects: 34
Study 24107462 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF)
Number of subjects: 452
Study 24107462 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate (MF)
Number of subjects: 452
Study 24107462 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 452
Study 24108117 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe sepsis treatment (no specific intervention details provided)
Number of subjects: 384
Study 24108222 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous dermo-epidermal skin grafts (DESG) with addition of human autologous thrombin activated autologous platelet concentrate (APC)
Number of subjects: 0
Study 24108222 — intervention group
Group type: COMPARATOR
Intervention: Autologous dermo-epidermal skin grafts (DESG)
Number of subjects: 0
Study 24108289 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior surgical approach
Number of subjects: 264
Study 24108289 — intervention group
Group type: COMPARATOR
Intervention: Posterior surgical approach
Number of subjects: 264
Study 24108289 — intervention group
Group type: EXPERIMENTAL
Intervention: Both anterior and posterior approaches
Number of subjects: 264
Study 24109169 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-piece hydrophobic acrylic intraocular lens (enVista model MX60)
Number of subjects: 122
Study 24109169 — intervention group
Group type: COMPARATOR
Intervention: FDA historical control
Number of subjects: 122
Study 24109561 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-administered treatment based on guided physical exercise for Major Depressive Disorder (MDD)
Number of subjects: 48
Study 24109561 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 48
Study 24111225 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forests classifier
Number of subjects: 0
Study 24111225 — intervention group
Group type: COMPARATOR
Intervention: Simple linear classifier
Number of subjects: 0
Study 24111638 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative measurements of FEV1 decline
Number of subjects: 3218
Study 24111638 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute measurements of FEV1 decline
Number of subjects: 3218
Study 24113022 — intervention group
Group type: EXPERIMENTAL
Intervention: Geometric annuloplasty ring
Number of subjects: 16
Study 24114122 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (IRIN) 150 mg/m2, Oxaliplatin (OX) 85 mg/m2, Capecitabine (CAP) 400 mg/m2, days 2-15
Number of subjects: 50
Study 24114122 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (IRIN) 75 mg/m2, Oxaliplatin (OX) 85 mg/m2, Capecitabine (CAP) 400 mg/m2
Number of subjects: 50
Study 24114122 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (IRIN) 150 mg/m2, Oxaliplatin (OX) 85 mg/m2, Capecitabine (CAP) 400 mg/m2
Number of subjects: 50
Study 24114122 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (IRIN) 150 mg/m2, Oxaliplatin (OX) 100 mg/m2, Capecitabine (CAP) 1600 mg/m2
Number of subjects: 50
Study 24114122 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (IRIN) 150 mg/m2
Number of subjects: 50
Study 24114122 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (IRIN) 100 mg/m2
Number of subjects: 50
Study 24114122 — intervention group
Group type: EXPERIMENTAL
Intervention: All genotype groups
Number of subjects: 50
Study 24114410 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurology attending physicians
Number of subjects: 3124
Study 24114410 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurosurgery attending physicians
Number of subjects: 3124
Study 24114410 — intervention group
Group type: COMPARATOR
Intervention: Surgery attending physicians
Number of subjects: 3124
Study 24114410 — intervention group
Group type: EXPERIMENTAL
Intervention: All specialties
Number of subjects: 3124
Study 24114456 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET-CT
Number of subjects: 58
Study 24114613 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI-B chemotherapy
Number of subjects: 31
Study 24114964 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 451
Study 24114964 — intervention group
Group type: COMPARATOR
Intervention: Platinum-based doublet therapy (carboplatin plus paclitaxel)
Number of subjects: 451
Study 24115141 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased expression of TGF-β
Number of subjects: 20
Study 24115141 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased expression of IL-4
Number of subjects: 20
Study 24115141 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased expression of IL-13
Number of subjects: 20
Study 24115141 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-4 and TGF-β expression
Number of subjects: 20
Study 24115141 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of IL-13 expression
Number of subjects: 20
Study 24117042 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescent-PCR (F-PCR)
Number of subjects: 130
Study 24117042 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunophenotypic response
Number of subjects: 130
Study 24117272 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide for patients with O6-methylguanine methyltransferase methylated tumors
Number of subjects: 0
Study 24117272 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (radiochemotherapy)
Number of subjects: 0
Study 24118452 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide (starting dose 1 mg/d in 52.6% of patients; 0.5 mg/d in 41.1%)
Number of subjects: 177
Study 24118452 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide
Number of subjects: 177
Study 24118452 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide initiation consistent with SPC
Number of subjects: 177
Study 24118452 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide after discontinuing previous cytoreductive therapy (CRT)
Number of subjects: 177
Study 24118844 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-coated Prolene mesh
Number of subjects: 161